Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Astellas to Place Greater Importance on China Business: Executive Katayanagi
March 28, 2012
- Nippon Shinyaku Submits NDA for Alcohol Abstinence Aid Acamprosate
March 28, 2012
- Ajinomoto, Takeda Submit Domestic Application for Once-Monthly Risedronate
March 28, 2012
- Anticancer Agents Set to Become Top Therapeutic Category in 2012: IMS Japan
March 28, 2012
- Nichi-Iko Provides Wholesalers with Monthly Supply Volume of Epadel Generic
March 27, 2012
- Epadel Generic in Short Supply at Sawai Pharmaceutical Due to Promotional Measures
March 26, 2012
- Daiichi Sankyo Submits NDA for Denosumab for Osteoporosis in Japan
March 26, 2012
- Daiichi Sankyo to Develop Unapproved Narcotic Analgesic in Japan
March 26, 2012
- Suzuken Establishes New Company Specializing in Rare Diseases
March 26, 2012
- Nexium No. 1 in MR Call Frequency in HP Market in February: Rep Track Survey
March 26, 2012
- Break of Day－Working to Optimize Settai Practices, Increase Financial Transparency: 3
March 26, 2012
- Break of Day－Working to Optimize Settai Practices, Increase Financial Transparency: 4
March 26, 2012
- Bayer Yakuhin to Initiate Drug Use-Result Survey on 10,000 Patients for Xarelto
March 23, 2012
- Shionogi Submits PIIa Clinical Trial Application for OncoTherapy’s AMD Vaccine
March 23, 2012
- Ajinomoto Pharmaceuticals to Market Gastritis/Ulcer Treatment Marzulene from July
March 23, 2012
- Astellas Vice Deputy Chairman Ishii Says Company R&D Strategy Focused on Personalized Medicine
March 22, 2012
- India’s Ministry of Commerce and Industry Kicks Off “Brand India Pharma” Campaign
March 22, 2012
- BD Japan Seeking Further Partnerships with Japanese Companies: Pres. Harris
March 22, 2012
- MTPC, Novartis Revise Package Insert of Imusera/Gilenya in Response to Overseas Death
March 22, 2012
- MSD, BIKEN Sign Domestic Marketing Agreement for 3 Flu Vaccines
March 22, 2012
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…